What is Biodermis?
For over three decades, Biodermis has functioned as a cornerstone in the field of post-operative care and dermatological recovery. The company specializes in advanced silicone gel sheeting, such as its flagship Epi-Derm line, alongside a comprehensive suite of ointments and compression foams. By catering to a sophisticated clientele of plastic surgeons, dermatologists, and clinical practitioners, Biodermis bridges the gap between medical necessity and aesthetic outcome. Their commitment to evidence-based skin care solutions has established them as a trusted partner in the clinical healing process, ensuring that patients receive high-quality, reliable interventions for complex surgical and traumatic scarring.
How much funding has Biodermis raised?
Biodermis has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in Biodermis
PPP
Public-Private Partnership
What's next for Biodermis?
With this recent strategic financing, Biodermis is well-positioned to accelerate its research and development initiatives, potentially diversifying its product portfolio to address emerging needs in regenerative medicine. The company is expected to leverage this capital to enhance its distribution channels, ensuring that its proprietary silicone technologies reach a broader international audience. As the demand for non-invasive aesthetic procedures continues to rise, Biodermis remains focused on maintaining its competitive edge through innovation and clinical excellence, effectively navigating the complexities of the late-stage growth environment to deliver long-term value to its stakeholders.
See full Biodermis company page
